Core Insights - Eton Pharmaceuticals has completed the acquisition of Increlex® (mecasermin injection) from Ipsen S.A., enhancing its portfolio in pediatric endocrinology [1][16] - Increlex® is the only FDA and EMA approved treatment for severe primary insulin-like growth factor 1 deficiency (SPIGFD) in pediatric patients aged 2 years and older [2][25] - The product is now available in the U.S. through AnovoRx, a specialty pharmacy, which will also manage the Eton Cares Program to assist patients [17][16] Group 1: Acquisition Details - The acquisition was financed using Eton's cash reserves and an expansion of its existing credit facility with SWK Holdings [3] - Ipsen will continue to distribute Increlex® outside the U.S. for a six-month transition period before Eton takes over commercialization [3] Group 2: Product Information - Increlex® is approved in 41 territories, including the U.S. and EU, with an estimated 200 patients in the U.S. and 900-1,000 in Europe suffering from SPIGFD [2] - The product is indicated for growth failure in pediatric patients with severe primary IGF-1 deficiency, defined by specific height and IGF-1 level criteria [25][26] Group 3: Patient Support and Accessibility - The Eton Cares Program will provide prescription fulfillment, insurance benefits investigation, educational support, and financial assistance for qualifying patients [17] - Co-pay assistance will be available to allow for $0 co-pays for eligible patients [17]
Eton Pharmaceuticals Closes Acquisition of Increlex® (mecasermin injection)